HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100CompaniesDeal TrackerResearch
Biotech

Moderna, Inc.

2
Articles
Mentioned
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
3.1
Relevance Score

Coverage Timeline

April 2026
Merck’s New R&D VP Bets Big on mRNA: What’s Really Shifting After COVID People Mentioned
Apr 11, 2026
Morgan, who spent the last five years leading Moderna’s infectious disease platform, is now tasked with shifting Merck’s decades-old vaccine engine into the mRNA era.
mRNA Vaccine Platforms in 2025: Chasing Infectious Disease Dollars Beyond COVID Pipeline Primary Subject
Apr 11, 2026
Moderna’s 2025 guidance for Spikevax revenue is even lower, at $1.6 billion.
Related Companies
GSK plc
2 shared
Pfizer Inc.
2 shared
OncoImmune, Inc.
1 shared
CEPI
1 shared
BioNTech SE
1 shared
CSL Limited
1 shared
Centers for Medicare and Medicaid Services
1 shared
Merck & Co., Inc.
1 shared
Sanofi S.A.
1 shared